Evidence map›Paper›PMID 39713402›Full record

ArticlebioRxiv : the preprint server for biology2025

Limitations of acyclovir and identification of potent HSV antivirals using 3D bioprinted human skin equivalents.

S Tori Ellison, Ian Hayman, Kristy Derr, Paige Derr, Shayne Frebert, Zina Itkin, Min Shen, Anthony Jones, Wendy Olson, Lawrence Corey and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

S Tori EllisonDepartment of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health; Rockville, Maryland 20850, USA.ORCID 0000-0002-5606-1668
Ian HaymanDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine; Seattle, WA 98195, USA.
Kristy DerrDepartment of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health; Rockville, Maryland 20850, USA.
Paige DerrDepartment of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health; Rockville, Maryland 20850, USA.
Shayne FrebertDepartment of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health; Rockville, Maryland 20850, USA.
Zina ItkinDepartment of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health; Rockville, Maryland 20850, USA.
Min ShenDepartment of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health; Rockville, Maryland 20850, USA.
Anthony JonesDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine; Seattle, WA 98195, USA.
Wendy OlsonDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine; Seattle, WA 98195, USA.
Lawrence CoreyDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine; Seattle, WA 98195, USA.
Anna WaldDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine; Seattle, WA 98195, USA.
Christine JohnstonDepartment of Medicine, University of Washington School of Medicine; Seattle, WA 98195, USA.
Youyi FongVaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center; Seattle, WA 98109, USA.
Marc FerrerDepartment of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health; Rockville, Maryland 20850, USA.
Jia ZhuDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine; Seattle, WA 98195, USA.

Funding

VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Modeling of human HSV infection: development of immune-competent 3D skin-on-chip with vascular perfusionR01AI143773 · NIAID · UNIVERSITY OF WASHINGTON · PI ZHU, JIA · 2020 to 2024
$2.7M
Cross talk between keratinocytes and skin-resident T-cells influences HSV recurrenceR01AI184778 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Jia Zhu · 2024 to 2026
$2.6M
Biofabricated 3-D skin model for antiviral drug discovery against human HSV infectionU18TR003208 · NCATS · UNIVERSITY OF WASHINGTON · PI ZHU, JIA · 2020 to 2021
$1.0M
NCATS NIH HHS U18 TR003208NIAID NIH HHS R01 AI143773NIAID NIH HHS R01 AI184778NIAID NIH HHS T32 AI007140
6 · The paper itself

Abstract

Herpes simplex virus (HSV) infection has worldwide public health concerns and lifelong medical impacts. The standard therapy, acyclovir, has limited efficacy in preventing HSV subclinical virus shedding, and drug resistance occurs in immunocompromised patients, highlighting the need for novel therapeutics. HSV manifests in the skin and mucosal epithelium. Here, we found acyclovir significantly less effective in skin-derived keratinocytes than donor-matched fibroblasts. To recapitulate

Identifiers

PMID39713402
PMCPMC11661117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.